MARKET

ADAP

ADAP

Adaptimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.40
+0.11
+2.08%
After Hours: 5.39 -0.01 -0.19% 19:23 09/17 EDT
OPEN
5.23
PREV CLOSE
5.29
HIGH
5.43
LOW
5.16
VOLUME
1.97M
TURNOVER
--
52 WEEK HIGH
10.93
52 WEEK LOW
3.370
MARKET CAP
839.52M
P/E (TTM)
-5.6250
1D
5D
1M
3M
1Y
5Y
Adaptimmune Shares Encouraging Data From Solid Tumor Trial
Benzinga · 4d ago
Adaptimmune's Cell Therapy Shows Antitumor Activity in Early Stage Study; Shares Down Midday
MT Newswires · 4d ago
BRIEF-Adaptimmune Announces Overall Response Rate Of 36% In Its Cancers Clinical Trial
reuters.com · 4d ago
SVB Leerink Maintains Market Perform on Adaptimmune Therapeutics, Raises Price Target to $7
SVB Leerink analyst Jonathan Chang maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Market Perform and raises the price target from $6 to $7.
Benzinga · 4d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 4d ago
--SVB Leerink Adjusts Adaptimmune Therapeutics PT to $7 From $6, Maintains Market Perform Rating
MT Newswires · 5d ago
Adaptimmune To Present Updated Data From Phase 1 SURPASS Trial At European Society For Medical Oncology Annual Meeting
Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 SURPASS trial in multiple solid tumors to be presented in a digital poster at the
Benzinga · 5d ago
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
- Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers - - Majority of patients experienced antitumor activity with a disease control rate ...
GlobeNewswire · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADAP. Analyze the recent business situations of Adaptimmune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADAP stock price target is 9.67 with a high estimate of 17.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 115
Institutional Holdings: 111.75M
% Owned: 71.88%
Shares Outstanding: 155.47M
TypeInstitutionsShares
Increased
25
3.95M
New
8
238.97K
Decreased
22
8.67M
Sold Out
12
1.40M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
David Mott
Chief Executive Officer/Director
Adrian Rawcliffe
Chief Financial Officer
Gavin Wood
Chief Operating Officer
William Bertrand
Senior Vice President
Elliot Norry
Other
John Lunger
Other
Helen Tayton-Martin
Non-Executive Director
James Noble
Non-Executive Independent Director
Lawrence Alleva
Non-Executive Independent Director
Ali Behbahani
Non-Executive Independent Director
Barbara Duncan
Non-Executive Independent Director
John Furey
Non-Executive Independent Director
Elliott Sigal
Non-Executive Independent Director
Tal Zvi Zaks
No Data
About ADAP
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its SPEAR T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (TCRs) against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company’s product pipeline includes ADP-A2M4, ADP-A2M4CD8, ADP-A2AFP and ADP-A2M10. Its ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types.

Webull offers kinds of Adaptimmune Therapeutics PLC - ADR stock information, including NASDAQ:ADAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADAP stock methods without spending real money on the virtual paper trading platform.